Dicloxacillin
A penicillinase-resistant isoxazolyl penicillin that resists staphylococcal beta-lactamase and is used orally to treat mild-to-moderate skin and soft tissue infections caused by staphylococci and streptococci. It must be taken on an empty stomach due to food-reduced absorption.
Masse moléculaire
470,3000 g/mol
LogP
2,90
TPSA
138,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …
Structure 2D
Cite this structure
Embed this structure
SMILES
Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
InChI
InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
Molecular Formula
C19H17Cl2N3O5S
HBD / HBA
2 / 7
Liaisons Rotatives
4
Atomes Lourds
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A penicillinase-resistant isoxazolyl penicillin that resists staphylococcal beta-lactamase and is used orally to treat mild-to-moderate skin and soft tissue infections caused by staphylococci and streptococci. It must be taken on an empty stomach due to food-reduced absorption.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.
Yes, Dicloxacillin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL893. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 18381. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dicloxacillin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dicloxacillin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dicloxacillin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dicloxacillin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dicloxacillin"></drugfyi-drug>